Matches in SemOpenAlex for { <https://semopenalex.org/work/W391305536> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W391305536 abstract "Biomarkers in cancer are present in both disease and normal tissue, which narrows the therapeutic window in order to avoid severe side effects. In this project, the concept of using protease activated affibody molecules to target the biomarker Human Epidermal Growth Factor Receptor 2 /HER2), was studied. HER2 is over expressed in certain types of breast cancer.Tumors have an up regulation in expression of specific proteases in their immediate surroundings. These proteases are quite specific to different tumors, making them ideal to activate prodrugs at the site of the tumor. This allows for a muck more specific targeting of the biomarkers present in disease tissue and thus increases the therapeutic window. One of the causes of breast cancer is through an over expression of HER2, which is responsible for 15.20% of all cases. This type of tumors produces certain types of proteases that are active in the area surrounding the tumor. One of these proteases is matrix mealloprotease 1 (MMP1).By linking two affibodies together, one that targets HER2 (ZHER2:342) and one antiidiotypic for the HER2-binding affiboday (ZE01), they will interact with each other and binding to HER2 can be blocked. By inserting a protease cleavage site into the linker, the dimer can be activated at the tumor site through cleavage, which releases the HER2-binding affibody and allows it to bind to its target and prevent dimerization. The protease cleavage site is a MMP1 stie with the amino acid sequence GPQAIAGQ.The constructs were cloned and analyzed using staphylococcal cell display and flow sytometry. It was shown that ZE01 effectively blocked binding of ZHER2:342 to HER2. Analysis of the constructs showed that incubation with MMP1 successfully cleaved the linker and allowed ZHER2:342 to bind HER2.The method is very promising, and can be used to specifically target other biomarkers as well in the future. Especially interesting targets are the biomarkers that are quite unspecific for a disease. This usually associates them with more severe side effects and less effective tretments." @default.
- W391305536 created "2016-06-24" @default.
- W391305536 creator A5018087577 @default.
- W391305536 date "2013-01-01" @default.
- W391305536 modified "2023-09-27" @default.
- W391305536 title "Protease-activated Affibody molecules for increasing the therapeutic window in cancer therapy" @default.
- W391305536 hasPublicationYear "2013" @default.
- W391305536 type Work @default.
- W391305536 sameAs 391305536 @default.
- W391305536 citedByCount "0" @default.
- W391305536 crossrefType "journal-article" @default.
- W391305536 hasAuthorship W391305536A5018087577 @default.
- W391305536 hasConcept C104317684 @default.
- W391305536 hasConcept C121608353 @default.
- W391305536 hasConcept C129527566 @default.
- W391305536 hasConcept C150194340 @default.
- W391305536 hasConcept C151730666 @default.
- W391305536 hasConcept C175156509 @default.
- W391305536 hasConcept C181199279 @default.
- W391305536 hasConcept C182220744 @default.
- W391305536 hasConcept C185592680 @default.
- W391305536 hasConcept C186268636 @default.
- W391305536 hasConcept C2776714187 @default.
- W391305536 hasConcept C2779281246 @default.
- W391305536 hasConcept C43369102 @default.
- W391305536 hasConcept C502942594 @default.
- W391305536 hasConcept C54355233 @default.
- W391305536 hasConcept C55493867 @default.
- W391305536 hasConcept C86803240 @default.
- W391305536 hasConcept C95444343 @default.
- W391305536 hasConceptScore W391305536C104317684 @default.
- W391305536 hasConceptScore W391305536C121608353 @default.
- W391305536 hasConceptScore W391305536C129527566 @default.
- W391305536 hasConceptScore W391305536C150194340 @default.
- W391305536 hasConceptScore W391305536C151730666 @default.
- W391305536 hasConceptScore W391305536C175156509 @default.
- W391305536 hasConceptScore W391305536C181199279 @default.
- W391305536 hasConceptScore W391305536C182220744 @default.
- W391305536 hasConceptScore W391305536C185592680 @default.
- W391305536 hasConceptScore W391305536C186268636 @default.
- W391305536 hasConceptScore W391305536C2776714187 @default.
- W391305536 hasConceptScore W391305536C2779281246 @default.
- W391305536 hasConceptScore W391305536C43369102 @default.
- W391305536 hasConceptScore W391305536C502942594 @default.
- W391305536 hasConceptScore W391305536C54355233 @default.
- W391305536 hasConceptScore W391305536C55493867 @default.
- W391305536 hasConceptScore W391305536C86803240 @default.
- W391305536 hasConceptScore W391305536C95444343 @default.
- W391305536 hasLocation W3913055361 @default.
- W391305536 hasOpenAccess W391305536 @default.
- W391305536 hasPrimaryLocation W3913055361 @default.
- W391305536 hasRelatedWork W1574972667 @default.
- W391305536 hasRelatedWork W1974949597 @default.
- W391305536 hasRelatedWork W2059979215 @default.
- W391305536 hasRelatedWork W2085605010 @default.
- W391305536 hasRelatedWork W2121821965 @default.
- W391305536 hasRelatedWork W2151856262 @default.
- W391305536 hasRelatedWork W3174680485 @default.
- W391305536 hasRelatedWork W3175288658 @default.
- W391305536 hasRelatedWork W1893703348 @default.
- W391305536 hasRelatedWork W2847198161 @default.
- W391305536 hasRelatedWork W2853032172 @default.
- W391305536 hasRelatedWork W2938180470 @default.
- W391305536 hasRelatedWork W2942683226 @default.
- W391305536 hasRelatedWork W2992792676 @default.
- W391305536 hasRelatedWork W2993355509 @default.
- W391305536 hasRelatedWork W3099128798 @default.
- W391305536 hasRelatedWork W3127068127 @default.
- W391305536 hasRelatedWork W3144561726 @default.
- W391305536 hasRelatedWork W3151715471 @default.
- W391305536 hasRelatedWork W3214300291 @default.
- W391305536 isParatext "false" @default.
- W391305536 isRetracted "false" @default.
- W391305536 magId "391305536" @default.
- W391305536 workType "article" @default.